Iovance Biotherapeutics, Inc. (IOVA) Stock Price & Analysis
Iovance Biotherapeutics, Inc. (IOVA) rose 1.03% to USD 8.79 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.
IOVA last closed at USD 8.7; the session ranged USD 8.64–8.9 on volume of 8,079,575 shares. Market capitalization is $3.98B, with a 52-week range of USD 1.76–9.36 (NGM). Source: Nexqual, September 8, 2026 at 05:44 UTC.
Key Statistics (as of September 8, 2026 at 05:44 UTC)
| Price | USD 8.79 |
|---|---|
| Change | ▲ 1.03% (up) |
| Previous Close | USD 8.7 |
| Open | USD 8.75 |
| Day Range | USD 8.64 – 8.9 |
| 52-Week Range | USD 1.76 – 9.36 |
| Volume | 8,079,575 shares |
| Market Cap | $3.98B |
| Exchange | NGM |
Technical Analysis (IOVA)
Nexqual's technical model rates IOVA "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 67.44 (neutral) |
| vs SMA50 | Above (USD 5.9) |
| MACD | 0.83 (positive) |
Analyst Ratings (IOVA)
Wall Street analysts rate IOVA "Buy" based on 9 analysts, with a mean price target of USD 10 (range USD 6–14), per Nexqual as of September 8, 2026 at 05:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 10 |
| High Target | USD 14 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 7 / 2 / 0 |
Earnings (IOVA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.1 |
| Revenue Estimate | $110.12M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.11 vs est -0.13 ▲ beat |
| 2026-03-31 | USD -0.19 vs est -0.15 ▼ miss |
| 2025-12-31 | USD -0.18 vs est -0.18 ▼ miss |
| 2025-09-30 | USD -0.25 vs est -0.26 ▲ beat |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financials & Fundamentals (IOVA)
| Total Revenue | $324.97M |
|---|---|
| Revenue Growth (YoY) | +65.70% |
| Gross Margin | +48.40% |
| Operating Margin | -52.26% |
| Profit Margin | -89.09% |
| ROE | -40.36% |
| Debt / Equity | 6.25 |
| Current Ratio | 4.35 |
| Total Cash | $297.67M |
| Total Debt | $46.00M |
| Free Cash Flow | $-187.79M |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financial Health Score (IOVA)
Nexqual rates Iovance Biotherapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 05:44 UTC.
| Growth | Strong — Revenue +61% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 48%, operating -52% |
| Balance Sheet | Strong — $298M cash vs $46M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$188M, burning cash |
| Efficiency | Critical — ROE -40%, ROA -20.3% |
Ownership (IOVA)
| Insider Ownership | +0.35% |
|---|---|
| Institutional Ownership | +70.61% |
| Shares Outstanding | 452.97M |
| Float | 394.33M |
| Short % of Float | +24.30% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Leadership (IOVA)
Iovance Biotherapeutics, Inc. is led by Frederick G. Vogt Esq. (age 51), Interim CEO, President, General Counsel, Corporate Secretary & Director, per Nexqual as of September 8, 2026 at 05:44 UTC.
| Interim CEO, President, General Counsel, Corporate Secretary & Director | Frederick G. Vogt Esq. (age 51) |
|---|---|
| Chief Financial Officer | Corleen M. Roche (age 59) |
| Chief Operating Officer | Igor P. Bilinsky (age 52) |
| Senior Vice President of Investor Relations & Corporate Communications | Sara Pellegrino |
| Executive Vice President of Human Resources | Tracy Winton |
Major Backers & Investors (IOVA)
Notable institutional backers of Iovance Biotherapeutics, Inc. include MHR Fund Management, LLC, Two Sigma Investments, LP, Millennium Management, according to Nexqual as of September 8, 2026 at 05:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MHR Fund Management, LLC | 6.39% |
| Two Sigma Investments, LP | 4.2% |
| Millennium Management | 1.88% |
| Palo Alto Investors Lp | 1.17% |
| Fidelity | 0.95% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 12.88% |
| BlackRock | 11.87% |
| State Street | 8.6% |
| Geode Capital | 2.28% |
| Dimensional Fund Advisors | 1.43% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
From Iovance Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
- The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
- The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | USD 2.48 | ▲ 1.22% |
| TWST | Twist Bioscience Corporation | USD 124.72 | ▼ 4.79% |
| NTLA | Intellia Therapeutics, Inc. | USD 12.74 | ▼ 0.16% |
| IBRX | ImmunityBio, Inc. | USD 8.08 | ▲ 1.64% |
| TGTX | TG Therapeutics, Inc. | USD 55.99 | ▼ 1.61% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.